{
  "id": 1488,
  "text": "In the second one1464, patients were randomized to receive cisplatin with concurrent EBRT, followed by brachytherapy or gemcitabine with the same radiation therapy.Although it was observed more frequent complete pathological response in the study arm (gemcitabine) than in the control arm $9 6 \\%$ versus $8 8 \\%$ ), no difference in terms of DFS or OS was reported between the two treatment groups.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: In the second one1464, patients were randomized to receive cisplatin with concurrent EBRT, followed by brachytherapy or gemcitabine with the same radiation therapy.Although it was observed more frequent complete pathological response in the study arm (gemcitabine) than in the control arm $9 6 \\%$ versus $8 8 \\%$ ), no difference in terms of DFS or OS was reported between the two treatment groups.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据所提供的信息，这种情况出现在宫颈癌的治疗研究中。在该研究中，患者被随机分配到接受顺铂结合外部放射治疗和后续腔内放射治疗的治疗组，或者接受吉西他滨结合相同放射治疗的治疗组。尽管吉西他滨组观察到更高的完全病理反应率，两组在无病生存期（DFS）和总体生存率（OS）方面没有差异。",
  "query": "在某临床试验中，患者被随机分配接受不同的治疗方案，一个组接受顺铂结合外部放射治疗，后续进行腔内放射治疗，而另一个组接受吉西他滨结合相同的放射治疗方案。尽管一个组观察到更高的完全病理反应率，两组在无病生存期和总体生存率方面没有差异。这种情况可能出现在哪种癌症的治疗研究中？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在某临床试验中，患者被随机分配接受不同的治疗方案，一个组接受顺铂结合外部放射治疗，后续进行腔内放射治疗，而另一个组接受吉西他滨结合相同的放射治疗方案。尽管一个组观察到更高的完全病理反应率，两组在无病生存期和总体生存率方面没有差异。这种情况可能出现在哪种癌症的治疗研究中？\n\n<reference text>: In the second one1464, patients were randomized to receive cisplatin with concurrent EBRT, followed by brachytherapy or gemcitabine with the same radiation therapy.Although it was observed more frequent complete pathological response in the study arm (gemcitabine) than in the control arm $9 6 \\%$ versus $8 8 \\%$ ), no difference in terms of DFS or OS was reported between the two treatment groups.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据所提供的信息，这种情况出现在宫颈癌的治疗研究中。在该研究中，患者被随机分配到接受顺铂结合外部放射治疗和后续腔内放射治疗的治疗组，或者接受吉西他滨结合相同放射治疗的治疗组。尽管吉西他滨组观察到更高的完全病理反应率，两组在无病生存期（DFS）和总体生存率（OS）方面没有差异。"
}